Skip to content
10-Q

Quarterly Report

60 DEGREES PHARMACEUTICALS, INC. SXTP SXTPW

0001213900-25-043779

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 15, 2025 1.47M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $3.45M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $1.66M
Stockholders Equity Q1 2025 · Mar 31, 2025 $4.11M
Stockholders Equity Q1 2025 · Dec 31, 2024 $4.04M
Current Liabilities Q1 2025 · Mar 31, 2025 $1.8M
Current Liabilities Q1 2025 · Dec 31, 2024 $1.66M
Total Liabilities Q1 2025 · Mar 31, 2025 $1.95M
Total Liabilities Q1 2025 · Dec 31, 2024 $1.8M
Current Assets Q1 2025 · Mar 31, 2025 $5.65M
Current Assets Q1 2025 · Dec 31, 2024 $5.39M
Total Assets Q1 2025 · Mar 31, 2025 $5.98M
Total Assets Q1 2025 · Dec 31, 2024 $5.76M
Short Term Investments Q1 2025 · Dec 31, 2024 $1.73M
Shares Diluted restated Q1 2025 · Mar 31, 2024 168.76K sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$1.14M
Eps Diluted restated Q1 2025 · Mar 31, 2024 $1.83
Eps Basic restated Q1 2025 · Mar 31, 2024 $1.83
Sga Expense Q1 2025 · Mar 31, 2024 $1.08M
Rd Expense Q1 2025 · Mar 31, 2024 $337.18K
Net Income Q1 2025 · Mar 31, 2024 $430.47K
Operating Income restated Q1 2025 · Mar 31, 2024 −$1.34M
Gross Profit restated Q1 2025 · Mar 31, 2024 $40.24K
Cost Of Revenue Q1 2025 · Mar 31, 2024 $65.44K
Revenue restated Q1 2025 · Mar 31, 2024 $105.67K